Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer

Radiation: Drug target found for radioresistance Drugs that block the androgen receptor (AR) protein can help make radiation-resistant breast tumors susceptible to ionizing therapy. Corey Speers from the University of Michigan, Ann Arbor, USA, and colleagues characterized the radiation sensitivity o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Corey Speers, Shuang G. Zhao, Ben Chandler, Meilan Liu, Kari Wilder-Romans, Eric Olsen, Shyam Nyati, Cassandra Ritter, Prasanna G. Alluri, Vishal Kothari, Daniel F. Hayes, Theodore S. Lawrence, Daniel E. Spratt, Daniel R. Wahl, Lori J. Pierce, Felix Y. Feng
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c2e0158317ef4f30b527bc09f5771091
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c2e0158317ef4f30b527bc09f5771091
record_format	dspace
spelling	oai:doaj.org-article:c2e0158317ef4f30b527bc09f57710912021-12-02T11:50:52ZAndrogen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer10.1038/s41523-017-0038-22374-4677https://doaj.org/article/c2e0158317ef4f30b527bc09f57710912017-08-01T00:00:00Zhttps://doi.org/10.1038/s41523-017-0038-2https://doaj.org/toc/2374-4677Radiation: Drug target found for radioresistance Drugs that block the androgen receptor (AR) protein can help make radiation-resistant breast tumors susceptible to ionizing therapy. Corey Speers from the University of Michigan, Ann Arbor, USA, and colleagues characterized the radiation sensitivity of 21 breast cancer cell lines and then paired the response data with the findings of a high-throughput drug screen to identify a medication called bicalutamide — an AR inhibitor — as one of the most potent agents for overcoming radiation resistance. The researchers then measured the expression of AR in more than 2100 human breast tumor samples and 51 breast cancer cell lines, and found that patients with triple-negative breast cancer, especially those who relapsed after radiation, had elevated levels of AR. Cell experiments with enzalutamide, a newer generation AR-blocking drug, confirmed that targeting AR helps reverse radiation resistance.Corey SpeersShuang G. ZhaoBen ChandlerMeilan LiuKari Wilder-RomansEric OlsenShyam NyatiCassandra RitterPrasanna G. AlluriVishal KothariDaniel F. HayesTheodore S. LawrenceDaniel E. SprattDaniel R. WahlLori J. PierceFelix Y. FengNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 3, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Corey Speers Shuang G. Zhao Ben Chandler Meilan Liu Kari Wilder-Romans Eric Olsen Shyam Nyati Cassandra Ritter Prasanna G. Alluri Vishal Kothari Daniel F. Hayes Theodore S. Lawrence Daniel E. Spratt Daniel R. Wahl Lori J. Pierce Felix Y. Feng Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
description	Radiation: Drug target found for radioresistance Drugs that block the androgen receptor (AR) protein can help make radiation-resistant breast tumors susceptible to ionizing therapy. Corey Speers from the University of Michigan, Ann Arbor, USA, and colleagues characterized the radiation sensitivity of 21 breast cancer cell lines and then paired the response data with the findings of a high-throughput drug screen to identify a medication called bicalutamide — an AR inhibitor — as one of the most potent agents for overcoming radiation resistance. The researchers then measured the expression of AR in more than 2100 human breast tumor samples and 51 breast cancer cell lines, and found that patients with triple-negative breast cancer, especially those who relapsed after radiation, had elevated levels of AR. Cell experiments with enzalutamide, a newer generation AR-blocking drug, confirmed that targeting AR helps reverse radiation resistance.
format	article
author	Corey Speers Shuang G. Zhao Ben Chandler Meilan Liu Kari Wilder-Romans Eric Olsen Shyam Nyati Cassandra Ritter Prasanna G. Alluri Vishal Kothari Daniel F. Hayes Theodore S. Lawrence Daniel E. Spratt Daniel R. Wahl Lori J. Pierce Felix Y. Feng
author_facet	Corey Speers Shuang G. Zhao Ben Chandler Meilan Liu Kari Wilder-Romans Eric Olsen Shyam Nyati Cassandra Ritter Prasanna G. Alluri Vishal Kothari Daniel F. Hayes Theodore S. Lawrence Daniel E. Spratt Daniel R. Wahl Lori J. Pierce Felix Y. Feng
author_sort	Corey Speers
title	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
title_short	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
title_full	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
title_fullStr	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
title_full_unstemmed	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
title_sort	androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/c2e0158317ef4f30b527bc09f5771091
work_keys_str_mv	AT coreyspeers androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT shuanggzhao androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT benchandler androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT meilanliu androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT kariwilderromans androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT ericolsen androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT shyamnyati androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT cassandraritter androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT prasannagalluri androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT vishalkothari androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT danielfhayes androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT theodoreslawrence androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT danielespratt androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT danielrwahl androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT lorijpierce androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer AT felixyfeng androgenreceptorasamediatorandbiomarkerofradioresistanceintriplenegativebreastcancer
_version_	1718395188892663808

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer

Ejemplares similares